All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 14th European Lupus Meeting 2024, the Lupus Hub was pleased to speak with Jill Buyon, New York University, New York, US. We asked, What are some of the key updates in the management of lupus during pregnancy?
What are some of the key updates in the management of lupus during pregnancy?
Firstly, Jill Buyon discusses two ongoing studies investigating pregnancy outcomes in women with anti-Ro antibodies or antiphospholipid antibodies. The first study, Surveillance and Treatment tO Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ, NCT04474223), focuses on monitoring maternal anti-Ro antibodies and using fetal heart rate monitoring to detect advanced disease, thereby offering possibilities for early intervention and improved monitoring strategies. The second study, IMProve Pregnancy in APS With Certolizumab Therapy (IMPACT, NCT03152058), aims to evaluate the efficacy of certolizumab in pregnant women with antiphospholipid syndrome.
Subscribe to get the best content related to lupus delivered to your inbox